Masiga Clet Wandui
Tropical Institute of Development Innovations , Entebbe , Uganda.
Front Bioeng Biotechnol. 2015 Oct 6;3:152. doi: 10.3389/fbioe.2015.00152. eCollection 2015.
The Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an internationally binding instrument addressing issues of biosafety. Biosafety refers to the need to protect human health and the environment from the possible adverse effects of the products of modern biotechnology. Accordingly, all countries to the convention are required to put in place regulatory mechanisms to enhance the safety of biotechnology in the context of the Convention's overall goal of reducing all potential threats to biological diversity, while taking into account the risks to human health. Therefore, each country party to the convention has its own procedures to enact laws to guide the safe use of biotechnology. In Uganda, the process involves the drafting of the bill by the first parliamentary counsel, approval by cabinet, first reading at the parliament, committal to the responsible parliamentary sessional committee, tabling of the bill for public hearing, consultations, and final approval. In Uganda, the Committee on Science and Technology is responsible for the Biosafety Bill. In March 2013, the Committee tabled the bill for public hearing and submissions from public institutions. There were comments supporting the passage of the Bill and comments in objection. The reasons for objection are mainly due to precaution, speculation, lack of knowledge about biotechnology and biosafety, and alleged influence from biosafety entrepreneurs. This article reviews these public views, revealing controversy and possible consensus to pass the bill.
《生物多样性公约》的《卡塔赫纳生物安全议定书》是一项处理生物安全问题的具有国际约束力的文书。生物安全是指保护人类健康和环境免受现代生物技术产品可能产生的不利影响的必要性。因此,该公约的所有缔约国都必须建立监管机制,以便在公约减少对生物多样性的所有潜在威胁这一总体目标的背景下,提高生物技术的安全性,同时考虑到对人类健康的风险。因此,该公约的每个缔约国都有自己的程序来制定法律,以指导生物技术的安全使用。在乌干达,这一过程包括由首席议会法律顾问起草法案、内阁批准、在议会进行一读、提交给负责的议会会议委员会、将法案提交公众听证、进行磋商以及最终批准。在乌干达,科学技术委员会负责生物安全法案。2013年3月,该委员会将法案提交公众听证并征求公共机构的意见。有支持该法案通过的意见,也有反对意见。反对的原因主要是出于预防、猜测、对生物技术和生物安全缺乏了解以及所谓的生物安全企业家的影响。本文回顾了这些公众意见,揭示了围绕该法案通过的争议以及可能达成的共识。